ArticleJAMA2021
Prevalence and Treatment of Diabetes in China, 2013-2018.
Article in JAMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 623 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Washed Microbiota Transplantation for Type 1 Diabetes Mellitus: a Real World Research
Health Effects of Vitamin K2 Supplementation on Skeletal Muscle and Neurological Function After Ischemic Stroke
Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Who cites it
623 citing papers in PubMed, 4 syntheses or guidelines pooled it, 891 citations in OpenAlex.
- Invasive non-typhoidal Salmonella infections in China (1961-2024): a retrospective systematic analysis of multicentre case reports.Journal of global health · 2026Pooled it
- National, regional, and provincial prevalence of glaucoma in China in 2020: an updated systematic review and modelling analysis.Journal of global health · 2025Pooled it
- The burden of prediabetes in low- and middle-income countries: a systematic review and meta-analysis.European journal of clinical nutrition · 2025Pooled it
- Risk factors for progression to type 2 diabetes in prediabetes: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Community-Based Personalised Lifestyle Intervention Guided by Intermittent Continuous Glucose Monitoring in Adults With Type 2 Diabetes: A Multicentre Randomised Controlled Trial.Diabetes, obesity & metabolism · 2026Trial
- Role-Playing-Based Physician Training and Metabolic Outcomes Among Patients With Type 2 Diabetes: A Cluster Randomized Clinical Trial.JAMA network open · 2026Trial
- Effects of mulberry twig alkaloids and canagliflozin in inadequately controlled type 2 diabetes: a randomized controlled study based on flash glucose monitoring.Scientific reports · 2026Trial
- Trial
- Effect of a Digital-Driven Physician-Pharmacist Collaborative Model for Diabetes in Primary Health Care: Cluster Randomized Trial.Journal of medical Internet research · 2026Trial
- WeChat-Based Intervention for Glycemic Control in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial.JMIR mHealth and uHealth · 2026Trial
- Effectiveness of the Mobile-Based Diabetes Little Helper Video Intervention on Medication Adherence Among Older Adults Living With Type 2 Diabetes Mellitus, Henan, China: Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial.Diabetes, obesity & metabolism · 2026Trial
- Trial
- Effects of aerobic exercise on vascular endothelial function and markers of oxidative stress and inflammation in individuals with impaired glucose tolerance: study protocol for a randomized controlled trial.Frontiers in endocrinology · 2026Trial
- Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system.Frontiers in endocrinology · 2026Trial
- Postprandial glycemic response, sensory, and appetite evaluation of highland barley-multigrain rice versus white rice in healthy Chinese adults: A randomized crossover study.Asia Pacific journal of clinical nutrition · 2025Trial
- Mobile App-Based Intervention and Cardiovascular Risk Factors in Patients With Uncontrolled Type 2 Diabetes: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers.European journal of drug metabolism and pharmacokinetics · 2025Trial
- Cardiometabolic medicine in China: Burden, challenges, and strategic priorities.Metabolism open · 2026Review
- Cardiometabolic comorbidity burden and low domain-specific health-promoting lifestyle scores among ethnic minority adults in Yunnan, China: A cross-sectional study.Preventive medicine reports · 2026Article
563 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Recent data on prevalence, awareness, treatment, and risk factors of diabetes in China is necessary for interventional efforts. Objective: To estimate trends in prevalence, awareness, treatment, and risk factors of diabetes in China based on national data. Design, Setting, and Participants: Cross-sectional nationally representative survey data collected in adults aged 18 years or older in mainland China from 170 287 participants in the 2013-2014 years and 173 642 participants in the 2018-2019 years. Exposures: Fasting plasma glucose and hemoglobin A1c levels were measured for all participants. A 2-hour oral glucose tolerance test was conducted for all participants without diagnosed diabetes. Main Outcomes and Measures: Primary outcomes were diabetes and prediabetes defined according to American Diabetes Association criteria. Secondary outcomes were awareness, treatment, and control of diabetes and prevalence of risk factors. A hemoglobin A1c level of less than 7.0% (53 mmol/mol) among treated patients with diabetes was considered adequate glycemic control. Results: In 2013, the median age was 55.8 years (IQR, 46.4-65.2 years) and the weighted proportion of women was 50.0%; in 2018, the median age was 51.3 years (IQR, 42.1-61.6 years), and the weighted proportion of women was 49.5%. The estimated prevalence of diabetes increased from 10.9% (95% CI, 10.4%-11.5%) in 2013 to 12.4% (95% CI, 11.8%-13.0%) in 2018 (P < .001). The estimated prevalence of prediabetes was 35.7% (95% CI, 34.2%-37.3%) in 2013 and 38.1% (95% CI, 36.4%-39.7%) in 2018 (P = .07). In 2018, among adults with diabetes, 36.7% (95% CI, 34.7%-38.6%) reported being aware of their condition, and 32.9% (95% CI, 30.9%-34.8%) reported being treated; 50.1% (95% CI, 47.5%-52.6%) of patients receiving treatment were controlled adequately. These rates did not change significantly from 2013. From 2013 to 2018, low physical activity, high intake of red meat, overweight, and obesity significantly increased in prevalence. Conclusions and Relevance: In this survey study, the estimated diabetes prevalence was high and increased from 2013 to 2018. There was no significant improvement in the estimated prevalence of adequate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.